Skip to main content
. 2022 Dec 6;8(12):e12118. doi: 10.1016/j.heliyon.2022.e12118

Figure 1.

Figure 1

Lipo2000 upregulates EphA2 expression by activating its transcription. Western blot results indicating the level of EphA2 in HCC cells with different treatments: (A) Vehicle (basal DMEM medium), lipo2000 (2.5 μg/mL)/siNC (5 nM) complexes and lipo2000 (2.5 μg/mL)/pEGFP-N plasmids (2.5 μg/mL) complexes. (B) Vehicle, siNC (5 nM), pEGFP-N plasmids (2.5 μg/mL), lipo2000 (1 μg/mL) and lipo2000 (2.5 μg/mL). (C) Vehicle, PEI (3 μg/mL), lipo2000 (2.5 μg/mL), and lipo3000 (3.75 μL). (D) Western blot results indicating the level of EphA2 in cells including 293T, HeLa, AGS, DLD1, and H460, treated with lipo2000 (2.5 μg/mL). (E) and (F) qPCR results demonstrating the relative expression of EphA2 mRNA and hnRNA in HCC cells treated by lipo2000. (G) qPCR results showing the relative expression of EphA2 mRNA co-treated with lipo2000 and actinomycin. (H) and (I) qPCR results showing the relative expression of EphA2 mRNA treated by lipo2000 at different times and doses. “Vehicle” means equal volume of pure DMEM medium. “Lipo” means lipo2000. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, “ns” means no significant difference.